Impact of Bamlanivimab Monoclonal Antibody Treatment on Hospitalization and Mortality Among Nonhospitalized Adults With Severe Acute Respiratory Syndrome Coronavirus 2 Infection

BACKGROUND: Monoclonal antibody treatment may prevent complications of coronavirus disease 2019 (COVID-19). We sought to quantify the impact of bamlanivimab monoclonal antibody monotherapy on hospitalization and mortality among outpatients at high risk of COVID-19 complications. METHODS: In this obs...

Descripción completa

Detalles Bibliográficos
Autores principales: Bariola, J Ryan, McCreary, Erin K, Wadas, Richard J, Kip, Kevin E, Marroquin, Oscar C, Minnier, Tami, Koscumb, Stephen, Collins, Kevin, Schmidhofer, Mark, Shovel, Judith A, Wisniewski, Mary Kay, Sullivan, Colleen, Yealy, Donald M, Nace, David A, Huang, David T, Haidar, Ghady, Khadem, Tina, Linstrum, Kelsey, Seymour, Christopher W, Montgomery, Stephanie K, Angus, Derek C, Snyder, Graham M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Major Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8241472/
https://www.ncbi.nlm.nih.gov/pubmed/34250192
http://dx.doi.org/10.1093/ofid/ofab254

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8241472/
https://www.ncbi.nlm.nih.gov/pubmed/34250192
http://dx.doi.org/10.1093/ofid/ofab254

Ejemplares similares